Exact Sciences Corp (MEX:EXAS)
MXN 872 0 (0%) Market Cap: 217.13 Bil Enterprise Value: 252.21 Bil PE Ratio: 0 PB Ratio: 3.40 GF Score: 80/100

Exact Sciences Corp at Robert W Baird Global Healthcare Conference Transcript

Sep 04, 2019 / 04:50PM GMT
Catherine Walden Ramsey Schulte
Robert W. Baird & Co. Incorporated, Research Division - Senior Research Analyst

All right. We're going to go ahead and get started. I'm Catherine Schulte, I cover Life Sciences and Diagnostics here at Baird. Very excited to have Exact Sciences presenting today. From the company, we have Jeff Elliott, CFO. If you have any questions at all during the presentation, you can e-mail them to [email protected], and I will pass them along to Jeff. So with that, I'll turn it over to Jeff for some introductory comments, and then we'll move into Q&A.

Jeffrey T. Elliott
Exact Sciences Corporation - CFO

Thank you, Catherine. It's great to be back here again at Baird. So we are coming off of a very strong quarter. In the second quarter, we grew by over 90%, we generated $200 million of revenue with 70% gross -- 74% gross margins. And today, our market share is under 6%. So there's a long runway ahead.

This market for colon cancer screening in the U.S. is 87 million people, so it's a huge market. Our long-term goal is to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot